share_log

Esperion Therapeutics Sees FY24 Revenues $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation

Benzinga ·  May 7 18:04
Esperion Therapeutics Sees FY24 Revenues $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment